Tuesday, 6 October 2026European Markets

EDP And NEOEN Have A High Dividend Yield And Return On Equity In The Utilities Sector.

Loading stream...

(vianews) - edp (edp.ls) is among this list of stock assets with the highest dividend rate and return on equity on the utilities sector.

financial asset price forward dividend yield return on equity
edp (edp.ls) €4.97 4% 10.6%
neoen (neoen.pa) €28.64 0.32% 2.78%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. edp (edp.ls)

4% forward dividend yield and 10.6% return on equity

edp - energias de portugal, s.a. engages in the generation, transmission, distribution, and supply of electricity in portugal, spain, france, poland, romania, italy, belgium, the united kingdom, greece, colombia, brazil, north america, and internationally. it operates through renewables, networks, and client solutions & energy management segments. the company primarily generates and sells electricity through hydro, ccgt, coal, wind, solar, nuclear, and cogeneration and waste sources. it has an installed capacity of 28 gw; and operates 380,788 kilometers of distribution network lines. the company is also involved in the supply of natural gas. in addition, it offers engineering, laboratory tests, professional training, and energy services, as well as property management services. the company's electricity and gas customers include domestic, industrial, commercial, agricultural, and others. edp - energias de portugal, s.a. was incorporated in 1976 and is headquartered in lisbon, portugal.

earnings per share

as for profitability, edp has a trailing twelve months eps of €0.21.

pe ratio

edp has a trailing twelve months price to earnings ratio of 23.66. meaning, the purchaser of the share is investing €23.66 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.6%.

revenue growth

year-on-year quarterly revenue growth grew by 45%, now sitting on 20.83b for the twelve trailing months.

more news about edp.

2. neoen (neoen.pa)

0.32% forward dividend yield and 2.78% return on equity

neoen s.a., an independent renewable energy production company, engages in the design, development, finance, construction project management, and operation of renewable energy power plants. the company operates solar, wind, and energy storage plants. it operates in argentina, australia, croatia, ecuador, united states, finland, france, ireland, italy, jamaica, mexico, mozambique, portugal, el salvador, sweden, and zambia. neoen s.a. was incorporated in 2008 and is headquartered in paris, france. neoen s.a. is a subsidiary of impala sas.

earnings per share

as for profitability, neoen has a trailing twelve months eps of €0.34.

pe ratio

neoen has a trailing twelve months price to earnings ratio of 84.24. meaning, the purchaser of the share is investing €84.24 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.78%.

more news about neoen.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com